Business Context and Reporting Period
Company: IGC Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 27, 2023
Event: Entry into a Material Definitive Agreement (ATM Sales Agreement).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a financing arrangement with the following parameters:
- Aggregate Offering Price: Up to $60 million in Common Stock.
- Reference Share Price: $0.29 per share (as of October 25, 2023).
- Commission Rate: 3.0% of gross proceeds paid to the sales agent.
- Legal Expense Cap: Up to $40,000 for the agent's legal counsel.
- Annual Maintenance Fee: $10,000.
Material Changes
The Company terminated its previous Sales Agreement dated January 13, 2021, with The Benchmark Company. Concurrently, it entered into a new Sales Agreement with A.G.P./Alliance Global Partners to facilitate the sale of shares via an "at the market" offering.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to sell shares from time to time based on market conditions and specific instructions regarding price, time, or size limits. The agent is not obligated to purchase shares on a principal basis.
Contingencies and Risks:
- Sales are subject to limitations under General Instruction I.B.6 of Form S-3.
- The agreement may be terminated by either party with five (5) days' prior written notice without liability.
- The agreement terminates upon the sale of all shares or the expiration of the underlying Registration Statement (third anniversary of January 4, 2021).
Investor Verification Checklist
- Verify the current share price relative to the $0.29 reference price to assess potential dilution impact.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific limitations on the amount of stock that may be sold.
- Monitor future filings for actual sales volumes and proceeds generated under this new agreement.
- Confirm the status of the underlying Shelf Registration Statement (Form S-3, File No. 333-251654).